Infliximab treatment of Crohn's disease in children: It's time to not go retro(spective)

American Journal of Gastroenterology

Volumn 98, Issue 1, 2003, Pages 5-6

  Hyams, Jeffrey S ^a  

^a Farmington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

CROHN DISEASE; EDITORIAL; EXPERIENCE; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY;

EID: 0037256579     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07170.x     Document Type: Editorial

References (5)

1. Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003;98:104-111.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359:1541-9.
3. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000;137:192-6.
4. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000;95:3189-94.
5. Markowitz J, Grancer K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.